Atreon Orthopedics, RenovoDerm Announce Merger

Atreon Orthopedics LLC and RenovoDerm LLC have merged, creating a company that aims to deliver synthetic biomaterials for tissue repair and remodeling. The new entity—Atreon Orthopedics Inc.—combines synergistic technologies, clinical and tissue-engineering expertise, and organizational scale, with multiple surgical platforms for long-term growth support.

Key strengths of the merged companies include:

• A comprehensive platform of synthetic biomaterial solutions designed for ease of use;
• Expanded clinical indications across orthopedic, trauma, sports medicine, foot/ankle, reconstructive, and complex wound applications;
• Unified Autobiologic technology for addressing the biologic challenges of tissue repair and remodeling; and
• Strengthened commercial infrastructure to support scalable growth across procedures, specialties and care settings

“This merger accelerates our ability to transform how surgeons approach the complexities of achieving durable tissue repair,” Atreon Orthopedics CEO Ronald Bracken said. “By combining Atreon’s leadership in tendon‑to‑bone healing with RenovoDerm’s advancements in complex wound reconstruction, we are creating a powerful platform that elevates performance, consistency, and clinical versatility in a vast array of surgical applications.”

The company’s synthetic scaffolds are precision-engineered to optimize the cellular microenvironment, promote organized native tissue remodeling, and deliver stronger, more consistent long‑term outcomes. RenovoDerm’s PHOENIX Wound Matrix, a next‑generation synthetic matrix designed for complex and chronic wounds, complements Atreon’s bio-inductive scaffolds, which have demonstrated reliable tendon‑to-bone healing in rotator cuff repair and other orthopedic applications. Together, the technologies establish a scalable platform that addresses the demands of diverse tissue environments and achieves consistent healing performance. The company is focused on expanding clinical evidence, accelerating product development, and strengthening its commercial reach.

“Our shared vision is to move beyond traditional augmentation and toward true biologic orchestration,” Bracken stated. “Traditional products often fail to address biologic gaps and industry shortfalls as surgeons seek a reliable solution that enables predictable, durable tissue repair without the risk of persistent inflammation or potential complications. Our Autobiologic portfolio offers a consistent and flexible solution to meet diverse surgical needs and enable broad market adoption. By uniting our teams and technologies, we are building a platform that supports surgeons across specialties and sets the stage for future innovation.”

Atreon Orthopedics designs synthetic biomaterials that work seamlessly with the body’s natural repair process. The company’s Autobiologic matrices is engineered to optimize the cellular microenvironment, promote native tissue remodeling, and deliver stronger, more reliable long-term outcomes. Its flagship technology, ROTIUM Bioresorbable Wick, supports reliable tendon‑to‑bone integration and is used in various musculoskeletal and orthopedic procedures. Atreon aims to establish its purpose‑built Autobiologic synthetic platform as the leading solution in tissue repair and remodeling.

RenovoDerm is a regenerative medicine company that develops and manufactures scientifically engineered synthetic polymer technologies to help advance clinical practice, improve patient outcomes, and reduce overall care costs. Its advanced products enhance tissue regeneration and promote rapid and definitive wound healing; those solutions can be used in all full- to partial-thickness wounds.